Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

AMPH Stock Forecast


Amphastar Pharmaceuticals stock forecast is as follows: an average price target of $66.00 (represents a 30.10% upside from AMPH’s last price of $50.73) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

AMPH Price Target


The average price target for Amphastar Pharmaceuticals (AMPH) is $66.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $66.00 to $66.00. This represents a potential 30.10% upside from AMPH's last price of $50.73.

AMPH Analyst Ratings


Buy

According to 1 Wall Street analysts, Amphastar Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AMPH stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Amphastar Pharmaceuticals Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 08, 2024David AmsellemPiper Sandler$66.00$43.3052.41%30.10%
May 23, 2024David AmsellemPiper Sandler$71.00$43.3163.93%39.96%
Mar 12, 2022David AmsellemPiper Sandler$35.00$34.302.04%-31.01%
Row per page
Go to

The latest Amphastar Pharmaceuticals stock forecast, released on Aug 08, 2024 by David Amsellem from Piper Sandler, set a price target of $66.00, which represents a 52.41% increase from the stock price at the time of the forecast ($43.30), and a 30.10% increase from AMPH last price ($50.73).

Amphastar Pharmaceuticals Price Target by Period


1M3M12M
# Anlaysts-12
Avg Price Target-$66.00$68.50
Last Closing Price$50.73$50.73$50.73
Upside/Downside-100.00%30.10%35.03%

In the current month, the average price target of Amphastar Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amphastar Pharmaceuticals's last price of $50.73. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 08, 2024Piper SandlerOverweightOverweightHold
Jun 27, 2024Piper SandlerOverweightOverweightHold
May 23, 2024Piper SandlerOverweightOverweightHold
Mar 12, 2022Piper SandlerOverweightOverweightHold
Row per page
Go to

Amphastar Pharmaceuticals's last stock rating was published by Piper Sandler on Aug 08, 2024. The company gave AMPH a "Overweight" rating, the same as its previous rate.

Amphastar Pharmaceuticals Financial Forecast


Amphastar Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$155.65M-$145.71M$140.02M$135.02M$120.13M$123.47M$120.37M$120.89M$112.20M$101.66M$103.02M$95.92M$83.43M$85.81M$84.69M$83.38M$80.14M$79.05M$79.79M$58.39M$56.67M
Avg Forecast$219.76M$216.01M$198.58M$189.95M$197.54M$194.67M$170.96M$174.65M$173.43M$174.63M$137.27M$137.27M$127.18M$125.98M$118.08M$113.33M$111.62M$103.25M$101.30M$96.87M$88.94M$91.23M$86.73M$82.90M$81.81M$78.57M$77.56M$76.22M$93.42M$44.08M
High Forecast$219.76M$216.01M$198.58M$189.95M$197.54M$203.17M$170.96M$174.65M$182.05M$174.63M$137.27M$137.27M$127.18M$125.98M$118.08M$113.33M$111.62M$103.25M$101.30M$96.87M$88.94M$91.23M$86.73M$82.90M$81.81M$78.57M$77.56M$76.22M$112.11M$52.89M
Low Forecast$219.76M$216.01M$198.58M$189.95M$197.54M$187.01M$170.96M$174.65M$164.80M$174.63M$137.27M$137.27M$127.18M$125.98M$118.08M$113.33M$111.62M$103.25M$101.30M$96.87M$88.94M$91.23M$86.73M$82.90M$81.81M$78.57M$77.56M$76.22M$74.74M$35.26M
# Analysts33334541311111111111559644741114
Surprise %--------0.90%-1.06%1.02%1.06%0.95%1.05%1.06%1.08%1.09%1.00%1.06%1.08%0.91%0.99%1.02%1.02%1.02%1.02%1.05%0.63%1.29%

Amphastar Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $174.65M, with a low forecast of $174.65M, and a high forecast of $174.65M. AMPH's average Quarter revenue forecast represents a 12.21% increase compared to the company's last Quarter revenue of $155.65M (Dec 23).

Amphastar Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33334541311111111111559644741114
EBITDA--------$53.98M-$36.90M$33.43M$37.83M$23.23M$24.82M$36.18M$33.67M$43.27M$20.31M$13.13M$-365.00K$13.05M$5.69M$12.13M$5.08M$7.20M$67.69M$3.94M$-5.08M$5.52M
Avg Forecast$34.33M$33.74M$31.02M$29.67M$30.85M$30.41M$26.70M$27.28M$27.09M$27.28M$21.44M$21.44M$19.87M$19.68M$18.44M$24.64M$17.43M$16.13M$15.82M$7.22M$13.89M$14.25M$13.55M$11.19M$12.78M$12.27M$12.12M$2.17M$-12.01M$3.94M
High Forecast$34.33M$33.74M$31.02M$29.67M$30.85M$31.73M$26.70M$27.28M$28.44M$27.28M$21.44M$21.44M$19.87M$19.68M$18.44M$29.57M$17.43M$16.13M$15.82M$8.66M$13.89M$14.25M$13.55M$13.43M$12.78M$12.27M$12.12M$2.60M$-9.60M$4.73M
Low Forecast$34.33M$33.74M$31.02M$29.67M$30.85M$29.21M$26.70M$27.28M$25.74M$27.28M$21.44M$21.44M$19.87M$19.68M$18.44M$19.71M$17.43M$16.13M$15.82M$5.78M$13.89M$14.25M$13.55M$8.95M$12.78M$12.27M$12.12M$1.73M$-14.41M$3.15M
Surprise %--------1.99%-1.72%1.56%1.90%1.18%1.35%1.47%1.93%2.68%1.28%1.82%-0.03%0.92%0.42%1.08%0.40%0.59%5.59%1.82%0.42%1.40%

1 analysts predict AMPH's average Quarter EBITDA for Mar 24 to be $27.28M, with a high of $27.28M and a low of $27.28M. This is -49.46% lower than Amphastar Pharmaceuticals's previous annual EBITDA (Dec 23) of $53.98M.

Amphastar Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33334541311111111111559644741114
Net Income--------$36.17M-$26.12M$26.03M$33.91M$15.87M$17.35M$24.25M$19.97M$29.55M$7.77M$5.04M$-6.27M$3.92M$-192.00K$3.95M$-1.03M$1.31M$47.79M$868.00K$-7.25M$893.00K
Avg Forecast$65.98M$62.46M$55.55M$52.35M$51.94M$51.42M$40.20M$40.25M$47.34M$36.17M$29.14M$27.67M$20.82M$20.47M$18.11M$16.84M$19.26M$12.49M$10.93M$2.77M$7.14M$7.29M$7.06M$3.64M$3.90M$3.47M$1.82M$477.40K$-17.12M$637.86K
High Forecast$65.98M$62.46M$55.55M$52.35M$51.94M$56.41M$40.21M$40.26M$52.78M$36.17M$29.14M$27.67M$20.82M$20.47M$18.11M$20.21M$19.26M$12.49M$10.93M$3.33M$7.14M$7.29M$7.06M$4.37M$3.90M$3.47M$1.82M$572.88K$-13.69M$765.43K
Low Forecast$65.98M$62.46M$55.55M$52.35M$51.94M$45.43M$40.19M$40.24M$40.81M$36.17M$29.14M$27.67M$20.82M$20.47M$18.11M$13.47M$19.26M$12.49M$10.93M$2.22M$7.14M$7.29M$7.06M$2.91M$3.90M$3.47M$1.82M$381.92K$-20.54M$510.29K
Surprise %--------0.76%-0.90%0.94%1.63%0.78%0.96%1.44%1.04%2.37%0.71%1.82%-0.88%0.54%-0.03%1.08%-0.26%0.38%26.23%1.82%0.42%1.40%

Amphastar Pharmaceuticals's average Quarter net income forecast for Mar 24 is $40.25M, with a range of $40.24M to $40.26M. AMPH's average Quarter net income forecast represents a 11.28% increase compared to the company's last Quarter net income of $36.17M (Dec 23).

Amphastar Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33334541311111111111559644741114
SG&A--------$21.74M-$19.00M$20.59M$16.10M$16.77M$15.73M$17.99M$14.70M$15.65M$18.69M$19.88M$15.82M$15.35M$19.95M$14.04M$13.98M$14.24M$15.42M$19.47M$12.72M$12.82M
Avg Forecast$35.06M$34.46M$31.68M$30.30M$31.51M$31.06M$27.27M$27.86M$27.67M$27.86M$21.90M$21.90M$20.29M$20.10M$18.84M$12.49M$17.81M$16.47M$16.16M$10.93M$14.19M$14.55M$13.84M$12.95M$13.05M$12.53M$12.37M$10.71M$30.05M$9.15M
High Forecast$35.06M$34.46M$31.68M$30.30M$31.51M$32.41M$27.27M$27.86M$29.04M$27.86M$21.90M$21.90M$20.29M$20.10M$18.84M$14.99M$17.81M$16.47M$16.16M$13.12M$14.19M$14.55M$13.84M$15.54M$13.05M$12.53M$12.37M$12.85M$36.06M$10.99M
Low Forecast$35.06M$34.46M$31.68M$30.30M$31.51M$29.83M$27.27M$27.86M$26.29M$27.86M$21.90M$21.90M$20.29M$20.10M$18.84M$9.99M$17.81M$16.47M$16.16M$8.74M$14.19M$14.55M$13.84M$10.36M$13.05M$12.53M$12.37M$8.57M$24.04M$7.32M
Surprise %--------0.79%-0.87%0.94%0.79%0.83%0.84%1.44%0.83%0.95%1.16%1.82%1.11%1.05%1.44%1.08%1.07%1.14%1.25%1.82%0.42%1.40%

Amphastar Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $27.86M, based on 1 Wall Street analysts, with a range of $27.86M to $27.86M. The forecast indicates a 28.15% rise compared to AMPH last annual SG&A of $21.74M (Dec 23).

Amphastar Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33334541311111111111559644741114
EPS--------$0.68-$0.54$0.54$0.70$0.32$0.35$0.50$0.42$0.62$0.16$0.11$-0.13$0.08-$0.09$-0.02$0.03$1.01$0.02$-0.16$0.02
Avg Forecast$1.27$1.20$1.07$1.01$1.00$0.99$0.77$0.77$0.91$0.69$0.56$0.53$0.40$0.39$0.35$0.36$0.37$0.24$0.21$0.18$0.14$0.14$0.14$0.09$0.07$0.07$0.04$0.04$0.19$0.05
High Forecast$1.27$1.20$1.07$1.01$1.00$1.08$0.77$0.77$1.01$0.69$0.56$0.53$0.40$0.39$0.35$0.36$0.37$0.24$0.21$0.18$0.14$0.14$0.14$0.09$0.07$0.07$0.04$0.04$0.23$0.06
Low Forecast$1.27$1.20$1.07$1.01$1.00$0.87$0.77$0.77$0.78$0.69$0.56$0.53$0.40$0.39$0.35$0.36$0.37$0.24$0.21$0.18$0.14$0.14$0.14$0.09$0.07$0.07$0.04$0.04$0.15$0.04
Surprise %--------0.75%-0.96%1.02%1.75%0.81%1.01%1.39%1.14%2.58%0.76%0.60%-0.95%0.57%-1.05%-0.27%0.45%28.86%0.50%-0.84%0.40%

According to 1 Wall Street analysts, Amphastar Pharmaceuticals's projected average Quarter EPS for Mar 24 is $0.77, with a low estimate of $0.77 and a high estimate of $0.77. This represents a 13.72% increase compared to AMPH previous annual EPS of $0.68 (Dec 23).

Amphastar Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IRWDIronwood Pharmaceuticals$4.19$11.67178.52%Buy
PCRXPacira BioSciences$16.57$40.00141.40%Hold
EVOEvotec SE$3.88$8.00106.19%Buy
EOLSEvolus$16.75$24.0043.28%Buy
ANIPANI Pharmaceuticals$58.19$79.0035.76%Buy
AMPHAmphastar Pharmaceuticals$50.73$66.0030.10%Buy
ALKSAlkermes$26.47$34.3829.88%Hold
COLLCollegium Pharmaceutical$33.46$41.5024.03%Buy
NBIXNeurocrine Biosciences$122.21$147.7020.86%Buy
SUPNSupernus Pharmaceuticals$33.97$38.0011.86%Buy
PBHPrestige Consumer Healthcare$74.05$82.0010.74%Buy
DCPHDeciphera Pharmaceuticals$25.59$26.322.85%Hold
PAHCPhibro Animal Health$23.18$18.67-19.46%Buy

AMPH Forecast FAQ


Yes, according to 1 Wall Street analysts, Amphastar Pharmaceuticals (AMPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of AMPH's total ratings.

Amphastar Pharmaceuticals (AMPH) average price target is $66 with a range of $66 to $66, implying a 30.10% from its last price of $50.73. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for AMPH stock, the company can go up by 30.10% (from the last price of $50.73 to the average price target of $66), up by 30.10% based on the highest stock price target, and up by 30.10% based on the lowest stock price target.

AMPH's average twelve months analyst stock price target of $66 does not support the claim that Amphastar Pharmaceuticals can reach $80 in the near future.

Amphastar Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $737.82M (high $746.32M, low $730.15M), average EBITDA is $115.24M (high $116.57M, low $114.05M), average net income is $183.81M (high $188.82M, low $177.8M), average SG&A $117.71M (high $119.06M, low $116.48M), and average EPS is $3.53 (high $3.63, low $3.42). AMPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $824.3M (high $824.3M, low $824.3M), average EBITDA is $128.75M (high $128.75M, low $128.75M), average net income is $236.34M (high $236.34M, low $236.34M), average SG&A $131.5M (high $131.5M, low $131.5M), and average EPS is $4.54 (high $4.54, low $4.54).

Based on Amphastar Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $593.24M, which missed the average analysts forecast of $622.59M by -4.71%. Apple's EBITDA was $196.99M, beating the average prediction of $97.25M by 102.57%. The company's net income was $137.54M, missing the average estimation of $140.32M by -1.98%. Apple's SG&A was $80.39M, missing the average forecast of $99.32M by -19.06%. Lastly, the company's EPS was $2.6, missing the average prediction of $2.7 by -3.57%. In terms of the last quarterly report (Dec 2023), Amphastar Pharmaceuticals's revenue was $155.65M, missing the average analysts' forecast of $173.43M by -10.25%. The company's EBITDA was $53.98M, beating the average prediction of $27.09M by 99.27%. Amphastar Pharmaceuticals's net income was $36.17M, missing the average estimation of $47.34M by -23.60%. The company's SG&A was $21.74M, missing the average forecast of $27.67M by -21.42%. Lastly, the company's EPS was $0.68, missing the average prediction of $0.91 by -25.24%